PT1632574E - Homólogos do factor de crescimento fibroblástico - Google Patents
Homólogos do factor de crescimento fibroblástico Download PDFInfo
- Publication number
- PT1632574E PT1632574E PT05021714T PT05021714T PT1632574E PT 1632574 E PT1632574 E PT 1632574E PT 05021714 T PT05021714 T PT 05021714T PT 05021714 T PT05021714 T PT 05021714T PT 1632574 E PT1632574 E PT 1632574E
- Authority
- PT
- Portugal
- Prior art keywords
- human
- polypeptide
- residue
- fhf
- amino acid
- Prior art date
Links
- 102000018233 Fibroblast Growth Factor Human genes 0.000 title abstract 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 title abstract 3
- 229940126864 fibroblast growth factor Drugs 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 claims abstract 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 31
- 125000000539 amino acid group Chemical group 0.000 claims abstract 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 14
- 210000000988 bone and bone Anatomy 0.000 claims 13
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 10
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims 9
- 108090000047 fibroblast growth factor 13 Proteins 0.000 claims 7
- 230000001737 promoting effect Effects 0.000 claims 7
- 102100028413 Fibroblast growth factor 11 Human genes 0.000 claims 5
- 108050003237 Fibroblast growth factor 11 Proteins 0.000 claims 5
- 102100035292 Fibroblast growth factor 14 Human genes 0.000 claims 5
- 108090000046 Fibroblast growth factor 14 Proteins 0.000 claims 5
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims 4
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 claims 4
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 claims 4
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 claims 4
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims 4
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims 4
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims 4
- 101001060265 Homo sapiens Fibroblast growth factor 6 Proteins 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 230000007547 defect Effects 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010010356 Congenital anomaly Diseases 0.000 claims 3
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims 3
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 claims 3
- 206010031264 Osteonecrosis Diseases 0.000 claims 3
- 230000008468 bone growth Effects 0.000 claims 3
- 238000002316 cosmetic surgery Methods 0.000 claims 3
- 239000004053 dental implant Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 230000035876 healing Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000000771 oncological effect Effects 0.000 claims 3
- 230000011164 ossification Effects 0.000 claims 3
- 230000001582 osteoblastic effect Effects 0.000 claims 3
- 230000002188 osteogenic effect Effects 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 238000002271 resection Methods 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims 2
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 claims 2
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims 2
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims 1
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 claims 1
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 abstract 6
- 125000003729 nucleotide group Chemical group 0.000 abstract 6
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
Claims (14)
- REIVINDICAÇÕES 1. Polipeptídeo seleccionado do grupo consistindo em: a) um polipeptídeo compreendendo uma sequência de aminoácidos, como mostrado na SEQ ID NO: 2 a partir de resíduo 28 (Glu) ao resíduo 175 (Met); e b) as moléculas de polipeptídeo que são pelo menos 80% idênticas à SEQ ID NO: 2 a partir do resíduo de aminoácido 28 (Glu) ao resíduo de aminoácido 175 (Met); para utilização na promoção da reparação de defeitos ósseo e deficiências; para uso na promoção da cicatrização óssea em cirurgia plástica; para uso no estímulo do crescimento ósseo em juntas não cimentadas protéticas e implantes dentários; para uso no aumento da formação óssea durante a distracção osteogénica; para uso no tratamento de outras doenças esqueléticas que podem ser tratadas por estimulação da actividade osteoblástica; para uso na reparação congénita, trauma-induzida, na ressecção oncológica do osso; ou para uso em reparação óssea após radiação induzida na osteonecrose.
- 2. Polipeptídeo seleccionado do grupo consistindo em: a) um polipeptídeo compreendendo uma sequência de aminoácidos, como mostrado na SEQ ID NO: 2 a partir de resíduo 28 (Glu) ao resíduo 196 (Lys); e b) as moléculas de polipeptídeos que são pelo menos 80% idênticas à SEQ ID NO: 2 a partir do resíduo de aminoácido 28 (Glu) ao resíduo de aminoácido 196 (Lys); para utilização na promoção da reparação de defeitos ósseo e deficiências; para uso na promoção da cicatrização óssea em cirurgia plástica; para uso no estímulo do crescimento ósseo em juntas não cimentadas protéticas e implantes dentários; para uso no aumento da formação óssea durante a distracção osteogénica; para uso no tratamento de outras doenças esqueléticas que podem ser tratadas por estimulação da actividade osteoblástica; para uso na reparação congénita, trauma-induzida, na ressecção oncológica do osso; ou para uso 1 em reparação óssea após radiação induzida na osteonecrose.
- 3. Polipeptideo seleccionado do grupo consistindo em: a) um polipeptideo compreendendo uma sequência de aminoácidos, como mostrado na SEQ ID NO: 2 a partir de resíduo 28 (Glu) ao resíduo 207 (Ala); e b) as moléculas de polipeptideos que são pelo menos 80% idênticas à SEQ ID NO: 2 a partir do resíduo de aminoácido 28 (Glu) ao resíduo de aminoácido 207 (Ala); para utilização na promoção da reparação de defeitos ósseo e deficiências; para uso na promoção da cicatrização óssea em cirurgia plástica; para uso no estímulo do crescimento ósseo em juntas não cimentadas protéticas e implantes dentários; para uso no aumento da formação óssea durante a distracção osteogénica; para uso no tratamento de outras doenças esqueléticas que podem ser tratadas por estimulação da actividade osteoblástica; para uso na reparação congénita, trauma-induzida, na ressecção oncológica do osso; ou para uso em reparação óssea após radiação induzida na osteonecrose.
- 4. Polipeptideo para uso de acordo com qualquer das reivindicações 1-3, em que o dito polipeptideo é seleccionado do grupo consistindo em: a) um polipeptideo composto por uma sequência de aminoácidos, como mostrado na SEQ ID NO: 2 a partir do resíduo 28 (Glu) ao resíduo 175 (Met); b) um polipeptideo composto por uma sequência de aminoácidos, como mostrado na SEQ ID NO: 2 a partir de resíduo 28 (Glu) ao resíduo 196 (Lys); c) um polipeptideo constituído de uma sequência de aminoácidos como mostrada em SEQ ID NO: 2 a partir de resíduo 28 (Glu) ao resíduo 207 (Ala).
- 5. Polipeptideo para uso de acordo com a reivindicação 4, para utilização na promoção da reparação de um defeito ósseo ou deficiência seleccionado entre fracturas fechadas, abertas e não-juntas. 2
- 6. Polipeptídeo para uso de acordo com qualquer das reivindicações 1-5, em que o dito polipeptídeo compreende ainda um residuo de metionina amino-terminal.
- 7. Polipeptídeo para uso de acordo com qualquer das reivindicações 1-5, em que o dito polipeptídeo ainda compreende uma sequência de sinal.
- 8. Polipeptídeo para uso de acordo com a reivindicação 7, em que o dita sequência de sinal é mostrada na SEQ ID NO: 2 a partir de um resíduo de aminoácido (Met) ao resíduo de aminoácido 27 (Ala).
- 9. Polipeptídeo para uso de acordo com a reivindicação 6, em que a desordem esquelética é a osteoporose ou artrite.
- 10. Polipeptídeo isolado seleccionado do grupo consistindo em: a) um polipeptídeo composto por uma sequência de aminoácidos, como mostrado na SEQ ID NO: 2 a partir do resíduo 28 (Glu) ao resíduo 175 (Met); acrescidos de um resíduo de metionina amino-terminal; b) um polipeptídeo consistindo numa sequência de aminoácidos como mostrada em SEQ ID NO: 2 a partir do resíduo 28 (Glu) ao resíduo 196 (Lys); além de um resíduo de metionina amino-terminal; c) um polipeptídeo consistindo numa sequência de aminoácidos como mostrada em SEQ ID NO: 2 a partir do resíduo 28 (Glu) ao resíduo 207 (Ala); acrescidos de um resíduo de metionina amino-terminal.
- 11. Polipeptídeo de acordo com a reivindicação 10, que compreende ainda uma sequência de sinal.
- 12. Polipeptídeo de acordo com a reivindicação 11, em que a dita sequência de sinal é mostrada na SEQ ID NO: 2a partir de um resíduo de aminoácido 1 (Met) ao resíduo de aminoácido 27 (Ala).
- 13. Polipeptídeo de acordo com qualquer das reivindicações 10-12 para o uso como um medicamento. 3
- 14. Composição farmacêutica compreendendo um polipeptídeo homólogo FGF purificado de acordo com qualquer das reivindicações 10-12, em combinação com um veículo farmaceuticamente aceitável. 4 FHF-2 -- -......- MAAAÍ AS5I. IRQKRQAfíESNS-DRVSASKSRSSPSKD5-R 38 FSF-10 -------------------------........................------ FHF-4 .......- - HAMIASGL IROKROAREOHk - DRPSASRRRSSPSKN * -R 37 FHF-2 ..........mMim WfWER--4fCSNACKCVSSPSKG^K 35 FHF-3 -.......- - MMt ASSLIRQKREVREPGB - SRPVSAQRRYCP - RGT - K 36 FSF4 mm ..........MS-GPGTMVALIPAVLLALL - APí-MGAAAPTAPN -G 37 FSFFHUMAN MAtGQKLF ÍTMSRGASRLQGTtWALVFLG IL -VGMVVP- - SPASTRAN - N 46 FSFrHUMAN -----.............- —............................ FSFiUUMWí .................................................. KSF-2 — -----MWKWI LTHCASAfPHLPGCCC-CCFLL LFLYSSVPVTC-Q 38 FSF? HUMAN -----------HHfâ(ILMLPTUYR-*S---*«CFHIiaveTISLAC-R 33 ZSI FRJZFGF ........-HV-SAPSACICLCLHFLLLCF-QVQ-.....VLVAEE-N 30 FSFB HUMAN -......- --HS-SPRSALSClUHLtVlCl-GAQEGPGRGPAL6R£L-A 37 FSF5“HUMAN -........MSISFLLLLFFSHULSA^AHGEKRLAPKGQPOPMTDRN 40 FGF9~Ht#IAN .................mGEVGMYFGVQCAVPFGNVPVLP- - VDSPVLLS-0 35 FGF3THUMAN —.............HGLIWLILL5UEP--------G.....WPAASPGA 23 FHF-l SLCERHV - - - LGVFSKVRFC5GR......—KRPVRRRFEPQLKGIVT 75 FGF-10 ................—---------------------MASKEPQLKSIVT 13 FHF-4 GLCMGNL—VD1FSKVRIR3LK..........KRRLRRQ-OPQLKGIVT 73 FHF-2 TSCDKNK-- -LNVFSRVKLFGSK..........KRRRRRP-EPQLKGIVT 73 ÍHF-3 SL CQKQL - - - L11LSK VRICGSRP -..........ARPDRGP-EPQLKSÍVT 73 FGF4 HUMAN TLEAEl£ RR-WESLVAl$LARL p WQPLE- AAVQSGAG9YLLG -1KRLR 84 FGF6“HUMAN TLLDS- -RG-WGTILSRSRAGl- --AG- -E- lAGVNWESSYLVG- IKRQR 36 FSF2~HUKAN -------- — - MAAGS1TTLPALPE * - * - *.....OSGSGAFPPSHFK0PK 30 ífiFlTilHAN ------------MAEGEITTFTALtE- - - — —KFíí— LPPGNYKKPK 27 K6F-2 ALeODHVSP-EAIRêSSSSFSSPSSAS------RHWYMHtGS-DVRWR 80 F5F7 HUMAN DMTPEÍ|M—ATNVNCS***5PE---------RHTRSY0Y(€G(2)IRVR 67 ZSI HUZFSF VOFSID--------------VEK- -—------- - - -QTRARODVSRKÍS.RLY 55 RSFB HUMAN SlFRAGR- - - EPGSVSQfWRF..............QSLTOSRRLIRTY 72 FGF5“HUMAN PISSSSR0SS$SAMS5SSASSSPAASIGSQSSSLE0SSFQ«SPS-GRRTS 89 FSF9“HUMAN HLfiQS---------E--AGGLPRGP...........AVTDLDHLKG-3UWR 64 FSF3IHUMAN RLRRO-----------------AGG............RGG7YEHLGG-APRRR 46 FHF-3 RLrSOQ'GYaWHP06TI0GTKDERSDYTLFNLIP76LR-VVAIQGW 122 FGF-10 RLFSOQ- -GYfLQMHPDGTIDGTKDENSDYTiFNLIP76LR-VVA1QGVK 60 FHF-4 RLYCR0-GYYlQMHPDGALDST!(OOSTRSTLFNLIP7GLR-V¥AlQGVt( 120 FHF-2 KLYSRQ--GYHLGLQAD6T1DGTKDE0STYTLFNLIP7GLR-WAIGGVQ 118 FHF-3 KLFCRQ--GF¥L0ANPE!GSiaGTPFDTSSFTHFNUP7G[R-WTIQSAK 120 FGF4 HUHAM RlYCíWGíGFHLQALPDGRISSAHADT - RD$Li£LSP>eS- WSÍ FGVA 132 FGF6“HUMAN RLYCNVGlGFHLGVLPDGRISâTHEEN - PYSLLEISTVERS-WSLFGVR 134 FGF2~HUMAN RLYCKNG-GFFlRIHPtíGRVDSVRFKSDPHIKLQLQAFERG-WSIKGVC 78 FSFrHUMAN LLYC5NG-GHFLRILPOGTYOSTRORSOQHIQLOISAESVS-EYYIK5TE 75 KGf-2 (ílFSFT-KYFLKIEWYSGTííKEfíCPYSILEITSYEIS-WAVKAlH 127 FSF7 HUMAN RLFCRT- -{^YLRIOKRGKVKGTQEMKNMYNÍMEIRTVAVG- IVA1KGVE 114 ZS! 8UZF6F QLYSRTS-GKHIQVlG-RRISARGEDGDKYAQLLVETDTFGSQVRIKGKt 103 FGFg HUMAN QLYSRTS-GKHVOVLAHKRHWtAEDGDPFMLIVtTDTFGSRVRVRGAE 121 FGF5“HUMAN SLYCRVSíGFHLQÍ YP06KW1SSHEWÍ-HLSVLEIFAV5QS- íVGJRSVF 137 FSFrHUMAN QIYCRT - -GFHLEIFPNQTIOSTRKOHSRFGILEFISIAVS-LVSIRSVD 111 FGF3“HUMAN KLYCAT--KYHLQLHPSGRVNSSL£MS-AYSÍLEÍTAYEVS-IVAIRSLF 92 *** - a* F1g. 1 FHF-1 FSF-1Q FHF-4 FHF-2 FHF-3 FGF4 HUMAN FGF6~MUMAN FSF2~HUMAN FGF1~HUMAN K8F-2 FGF7 HUMAN ZSí RUZFGF FSFB HUMAH FSF5“HliMAN F6E9~HUMAN FSF3"HUMAN TEFYLCMNRKGKLYGKPI^TSKECVntKVLEHHYTAlMSAKYSG.....148 TGLY ICHHKKGid IAKSNSKGKOCVFTE IVLENNYTALQNAKYEG.....166 FHF-1 FGF-10 FHF-4 FHF-2 FHF-3 F6F4 HUMAN FGF6~HUMAN FGF2”HUMAN FGFOUMAN KSF-2 F6F7 HUMAN ZSI HSJ7FGF FGF8 HUMAN FGF5~HIjMAM FSF9~HUMAN FGF3HUHAM MFIA15KN6KTKKG- -HRVSPTHKVTHFLPRL.....2Ô6 TYIALSKYGRVKRG- -SKVSPÍKmHFLPRI.......208 FHF-1 FGF-10 FHF-4 FHF-2 FHF-3 FGF4 HUMAN FGF6~HUMAN FGF2HUMAN FGFrHUHAM K6P-2 FGF7 HUMAíí 26! RUZFGF FGFB HUMAN fgfshuman FGF9~HUHAN FGF3~HUMAN MVRQLGSSLPRPPGKGVQPRRRRQKGSPDNt íPSHVGASRLGSQLSASAH 239 Fig. 2 ASL YVAMMGEGYLYSSDV - FTPEÇKFKESVFENYWI YSSÍl YRQGESG - 170 ASLYV/WNGEGYlY$$DV-FTP£CKFKESVFENWÍYSSTLYROQE$G- 108 TGLYlAHHGEGYLYFSEl-FTPECKFKESVFFNYWIYSSKLYRQQESG- 168 IXlYlAHNSEGYLYTSÉL-FTPECKFKESVFEHYYVTYSSMiYfiGQQSG* 166 tGHYHAHNAEGLLYSSPH-FTAECRFKECVFENYWLYASALYRQRRSG- 168 SRFFVAMSSKSKLYGSPF-FTDECTFKEILLPNNYNAYESYKYPG--— 176 SAtFVAHHSfCGRLYAFS-FQEECKFRETlLPHPÍYHAYESOlYíB.....178 ANR Y LAMKEDGRL LASKC-VTDECFFFERL ESNNYNTYRSRKYTS------ 122 TGQ YLAfiDTEfâLL YGSOT-PNEECLFLERLEENHYHTYI5KKHAEK --N - 121 SNYYLAMMííKGKLYGSKE-FMNOCKUCERIEEHGYHWASFNWQHH-G- 173 SFF Y LAMNKEEaCL YAKKE - CHEOCNFKEl IIENHYNTYASAKWTHN - -G - 160 SNKFLAHSFKGKLHASAK-FTGOCKFRERFOENSYHTYASAIHRTEKTG- 185 SGLYLGWEKGELYGSEK-UQECVFREQFEENWYNTY5SNLYKHVDT2- 159 SGRYLAHHiCRGRLYtôEH-YSAECEFVERIHElGYHTYASRLYRTVSSTP 141 «. * * * .* . * * * 1 * * » ► * * ---------RAWFIGINKEGÍHHKG--NRVKKTKPSSHFVPKFÍEVCMYR 209 .....- - - - RAWFLGL NKE6Q1MKG - - NRVEKTKPSSHF VPKPI EVCMYR 147 .........RAVJFIGLNKEGQAMKS- - NRVWCTKPAAHFLPKPLEVAMYR 207 .........RGWYlGtMEÔElHKG--NHYKKNKPAAHFLPKPLKVAMYK 205 .........RAWYLGIDKESQVMKG--NRVIQCTKAAAHFLPKLIEVAHYQ 207 - ..........WYVALKRTGQYKLG-- SKTGPGQKAÍLFLPMSAKS----155 .....-.....WFVGIKKNGSCKRG-PRTHYGQKAÍLFLPLPVSSD- - 155 - ------RQMYVALNGKGAPRRG - -GKTRRKNT5AHFLPMWHS- - - - 208 ——~ «GEMFVALNQKGÍPVRG - - KKTKKEQKTAHFLPMAIT.....194 ...........WYVQFTKKGRPRKG-PKTRENQQDVHFHKRYPKGQPEL 185 ...........WYMAFTRKGRPRK6- -SKTRQHQREVNFMKRlPRGHHTT 203 .......- -REWYVALHKRGKAKRGCSPRVKPCHISTHFLPRFKQSEO-P 225 -------- -RRYYVALM3GTPREG- -TRTKRHGKFTHFLPRPVDPOKVP 198 GARRQPSAERLWYVSVNSKGRPRRG- -FKTRRTQKS5LFIPRVLOHRDHE 189 ::,. * * ;·, *; EPSIHEÍGERQ- - - -GRS- -RKSSGTPTMHGGKVVNQD5T- ------ 243 EPSIBEIGENK—GVQ~ -GKFWTPP......................... 168 £PSLRDVGETVPKP-GVTPSKSTSASAIMNGGKPVNtôKTT--------- 247 EPSLHOlTEFSRSG-SGTPTKSRSVSGVLHGGKSNSIfliEST- ——- 245 EPSLHSVPEAS.......P--SSPPAP-...........-..........225 GKPFKYTTVTK.....RSRR-IRPTHPA.....................207 EOSLRFEFLNYPPF-TRSLRGSQRTWAPEPR...................233 ELSFTyTVPEKKNP-PSPIKSKIPLSAPRmsVKYRLKFRFG--------- 268 ELYKDILSQS—............................—-------- 208co D)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2864696P | 1996-10-16 | 1996-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1632574E true PT1632574E (pt) | 2011-03-17 |
Family
ID=21844629
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97910128T PT931148E (pt) | 1996-10-16 | 1997-10-16 | Homologos do factor de crescimento fibroblastico |
PT05021714T PT1632574E (pt) | 1996-10-16 | 1997-10-16 | Homólogos do factor de crescimento fibroblástico |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97910128T PT931148E (pt) | 1996-10-16 | 1997-10-16 | Homologos do factor de crescimento fibroblastico |
Country Status (20)
Country | Link |
---|---|
US (3) | US5989866A (pt) |
EP (4) | EP2264175B1 (pt) |
JP (1) | JP4091122B2 (pt) |
KR (1) | KR100611063B1 (pt) |
CN (1) | CN1127568C (pt) |
AT (2) | ATE491029T1 (pt) |
AU (1) | AU725551B2 (pt) |
BR (2) | BRPI9712348C8 (pt) |
CA (1) | CA2269083C (pt) |
CZ (1) | CZ299288B6 (pt) |
DE (2) | DE69740074D1 (pt) |
DK (2) | DK0931148T3 (pt) |
ES (3) | ES2258788T3 (pt) |
HK (2) | HK1089206A1 (pt) |
IL (1) | IL129379A (pt) |
NO (1) | NO326459B1 (pt) |
PL (1) | PL192537B1 (pt) |
PT (2) | PT931148E (pt) |
UA (1) | UA75316C2 (pt) |
WO (1) | WO1998016644A1 (pt) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728546A (en) | 1995-06-05 | 1998-03-17 | Human Genome Sciences, Inc. | Fibroblast growth factor 13 |
US6518236B1 (en) * | 1996-10-16 | 2003-02-11 | Zymogenetics, Inc. | FGF homologs |
US20050043234A1 (en) * | 1996-10-16 | 2005-02-24 | Deisher Theresa A. | Novel FGF homologs |
AU5433798A (en) * | 1996-11-27 | 1998-06-22 | Human Genome Sciences, Inc. | Fibroblast growth factor-13 |
US6207442B1 (en) * | 1997-10-16 | 2001-03-27 | Zymogenetics, Inc. | Plasmid construction by homologous recombination |
AU3076099A (en) * | 1998-03-09 | 1999-09-27 | Chiron Corporation | Human fgf gene and gene expression products |
US6331523B1 (en) | 1998-03-12 | 2001-12-18 | Genentech, Inc. | Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5 |
EP1061943B1 (en) * | 1998-03-12 | 2002-10-23 | Genentech, Inc. | Use of fgf-5 polypeptides for preventing the death of retinal neurons and treating ocular diseases |
EP1098974A2 (en) * | 1998-07-20 | 2001-05-16 | Curagen Corporation | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
US6537554B1 (en) | 1998-09-10 | 2003-03-25 | Curagen Corporation | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
US6251079B1 (en) | 1998-09-30 | 2001-06-26 | C. R. Bard, Inc. | Transthoracic drug delivery device |
US6635249B1 (en) * | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
CN1180841C (zh) * | 1999-09-30 | 2004-12-22 | 科研制药株式会社 | 胸骨切开术后促进胸骨愈合的方法 |
AU1804201A (en) * | 1999-12-02 | 2001-06-12 | Zymogenetics Inc. | Methods for targeting cells that express fibroblast growth receptor-3 or-2 |
US7470665B2 (en) | 1999-12-02 | 2008-12-30 | Zymogenetics, Inc. | Methods for targeting cells that express fibroblast growth receptor-3 or -2 |
US7291597B2 (en) * | 2000-04-06 | 2007-11-06 | Franco Wayne P | Growth factor therapy mobilization of stem cells into the peripheral blood |
US7288521B2 (en) * | 2000-04-06 | 2007-10-30 | Franco Wayne P | Growth factor therapy mobilization of stem cells into the peripheral blood |
IL139380A0 (en) * | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
WO2003012053A2 (en) * | 2001-08-01 | 2003-02-13 | New York University | Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis |
ATE429249T1 (de) * | 2001-12-28 | 2009-05-15 | Kyowa Hakko Kogyo Kk | Anti-fgf-8 antikörper gegen arthritis |
IL149562A0 (en) | 2002-05-09 | 2002-11-10 | Prochon Ltd | Fgf variants and methods for use thereof |
ATE312605T1 (de) * | 2002-06-29 | 2005-12-15 | Aquanova Ger Solubilisate Tech | Isoflavonkonzentrate sowie verfahren zu ihrer herstellung |
US7482427B2 (en) * | 2002-08-20 | 2009-01-27 | Biosurface Engineering Technologies, Inc. | Positive modulator of bone morphogenic protein-2 |
US7166574B2 (en) | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
US7598224B2 (en) | 2002-08-20 | 2009-10-06 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
US8227411B2 (en) | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
AU2003279835B2 (en) | 2002-10-07 | 2009-09-10 | Zymogenetics, Inc. | Methods of administering FGF18 |
JP2007524376A (ja) * | 2003-03-27 | 2007-08-30 | チルドレンズ ホスピタル メディカル センター | 軟骨形成を誘導するfgf−18タンパク質、標的タンパク質、およびそれぞれをコードするヌクレオチド配列の使用 |
US7067123B2 (en) * | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US7414028B1 (en) * | 2004-02-04 | 2008-08-19 | Biosurface Engineering Technologies, Inc. | Growth factor analogs |
US20060024347A1 (en) * | 2004-02-10 | 2006-02-02 | Biosurface Engineering Technologies, Inc. | Bioactive peptide coatings |
US7528105B1 (en) | 2004-02-10 | 2009-05-05 | Biosurface Engineering Technologies | Heterodimeric chain synthetic heparin-binding growth factor analogs |
US20080227696A1 (en) | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
US7671012B2 (en) | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
AU2005269995C1 (en) | 2004-07-06 | 2011-12-01 | Zymogenetics, Inc. | Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use |
US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
PT1828239E (pt) * | 2004-12-10 | 2011-10-27 | Zymogenetics Inc | Produção de fgf18 em hospedeiros procarióticos |
US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
JP2009508596A (ja) | 2005-09-19 | 2009-03-05 | ヒストジェニックス コーポレイション | 細胞支持基材及びその調製方法 |
JPWO2007099953A1 (ja) * | 2006-02-28 | 2009-07-16 | 国立大学法人 東京医科歯科大学 | 歯根形成促進剤及び歯根形成促進方法 |
WO2007119240A2 (en) * | 2006-04-17 | 2007-10-25 | Hepacore Ltd. | Methods for bone regeneration using endothelial progenitor cell preparations |
US7820172B1 (en) | 2006-06-01 | 2010-10-26 | Biosurface Engineering Technologies, Inc. | Laminin-derived multi-domain peptides |
CA2692240C (en) | 2006-06-22 | 2018-03-13 | Biosurface Engineering Technologies, Inc. | Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis |
EP2083846B1 (en) | 2006-09-28 | 2015-07-15 | Hepacore Ltd. | N-terminal fgf variants having increased receptor selectivity and uses thereof |
US7595296B1 (en) * | 2006-11-09 | 2009-09-29 | Florida State University Research Foundation, Inc. | Mutant polypeptides of fibroblast growth factor 1 |
EP2127674B1 (en) * | 2007-02-19 | 2013-04-24 | National Institute of Advanced Industrial Science and Technology | Use of FGF18 inhibitors as hair regrowth promoter |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
US7659379B1 (en) * | 2007-05-24 | 2010-02-09 | Florida State University Research Foundation, Inc. | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency |
US20090054984A1 (en) | 2007-08-20 | 2009-02-26 | Histogenics Corporation | Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects |
US8685107B2 (en) | 2007-07-03 | 2014-04-01 | Histogenics Corporation | Double-structured tissue implant and a method for preparation and use thereof |
CA2717725A1 (en) | 2008-03-05 | 2009-09-11 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
TWI527590B (zh) | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Fgf-18之凍乾調配物 |
CN104736723B (zh) | 2012-08-06 | 2017-10-31 | 默克专利有限公司 | 用于预测对fgf‑18化合物的响应性的遗传标记 |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
KR102261934B1 (ko) * | 2015-01-23 | 2021-06-08 | (주) 에스바이오메딕스 | Mbp-fgf2를 이용한 3차원 섬유아세포집합체를 제조하는 방법 |
EP3250925B1 (en) | 2015-01-29 | 2019-04-10 | Ares Trading S.A. | Immunoassays for highly positively charged proteins |
EP3322736B1 (en) | 2015-07-15 | 2021-09-01 | Prosit Sole Biotechnology (Beijing) Co., Ltd | Fusion polypeptides and methods of use |
AU2018337686B2 (en) | 2017-09-21 | 2023-04-20 | Merck Patent Gmbh | Fusion protein comprising an FGF-18 moiety |
AU2018343980A1 (en) | 2017-09-29 | 2020-04-02 | Merck Patent Gmbh | Inflammatory biomarkers for predicting responsiveness to FGF-18 compound |
HUE058786T2 (hu) | 2017-09-29 | 2022-09-28 | Merck Patent Gmbh | FGF-18 vegyületre vonatkozó válaszkészség elõrejelzésére szolgáló metabolikus biomarkerek |
CN108324928B (zh) * | 2018-03-05 | 2020-09-08 | 哈尔滨医科大学 | 重组人成纤维细胞生长因子-5在促骨折愈合中的应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK368882A (da) | 1981-08-25 | 1983-02-26 | Alan John Kingsman | Expessions vektorer |
US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
US4945778A (en) | 1984-01-30 | 1990-08-07 | Weyer Paul P | Fluid-power device with rollers |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
US4990446A (en) | 1984-12-06 | 1991-02-05 | Labofina, S.A. | Promoters for the expression of foreign genes in yeast, plasmids comprising them, and use thereof for the production of polypeptides |
US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US5439818A (en) * | 1985-09-12 | 1995-08-08 | Scios Nova Inc. | DNA encoding human recombinant basic fibroblast growth factor |
US5604293A (en) * | 1985-09-12 | 1997-02-18 | Scios Inc. | Recombinant human basic fibroblast growth factor |
US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
AU5103293A (en) | 1992-09-14 | 1994-04-12 | Oklahoma State University | Immortalized cells and uses therefor |
US5773252A (en) * | 1995-06-05 | 1998-06-30 | Human Genome Sciences, Inc. | Fibroblast growth factor 15 |
JP2000500014A (ja) | 1995-11-09 | 2000-01-11 | ザイモジェネティクス,インコーポレイティド | ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法 |
-
1997
- 1997-10-16 PT PT97910128T patent/PT931148E/pt unknown
- 1997-10-16 US US08/951,822 patent/US5989866A/en not_active Expired - Lifetime
- 1997-10-16 EP EP10176653A patent/EP2264175B1/en not_active Expired - Lifetime
- 1997-10-16 AT AT05021714T patent/ATE491029T1/de active
- 1997-10-16 AU AU47583/97A patent/AU725551B2/en not_active Expired
- 1997-10-16 JP JP51857798A patent/JP4091122B2/ja not_active Expired - Lifetime
- 1997-10-16 KR KR1019997003306A patent/KR100611063B1/ko not_active IP Right Cessation
- 1997-10-16 ES ES97910128T patent/ES2258788T3/es not_active Expired - Lifetime
- 1997-10-16 PL PL332851A patent/PL192537B1/pl unknown
- 1997-10-16 AT AT97910128T patent/ATE318906T1/de active
- 1997-10-16 EP EP05021714A patent/EP1632574B1/en not_active Expired - Lifetime
- 1997-10-16 BR BRPI9712348A patent/BRPI9712348C8/pt not_active IP Right Cessation
- 1997-10-16 DE DE69740074T patent/DE69740074D1/de not_active Expired - Lifetime
- 1997-10-16 CN CN97199827A patent/CN1127568C/zh not_active Expired - Lifetime
- 1997-10-16 EP EP10185113A patent/EP2339002A1/en not_active Withdrawn
- 1997-10-16 BR BRPI9712348-0B1A patent/BR9712348B1/pt not_active IP Right Cessation
- 1997-10-16 IL IL129379A patent/IL129379A/en not_active IP Right Cessation
- 1997-10-16 WO PCT/US1997/018635 patent/WO1998016644A1/en active IP Right Grant
- 1997-10-16 ES ES10176653T patent/ES2403880T3/es not_active Expired - Lifetime
- 1997-10-16 DK DK97910128T patent/DK0931148T3/da active
- 1997-10-16 DE DE69735352T patent/DE69735352T2/de not_active Expired - Lifetime
- 1997-10-16 UA UA99042170A patent/UA75316C2/uk unknown
- 1997-10-16 ES ES05021714T patent/ES2357215T3/es not_active Expired - Lifetime
- 1997-10-16 CZ CZ0131599A patent/CZ299288B6/cs not_active IP Right Cessation
- 1997-10-16 CA CA002269083A patent/CA2269083C/en not_active Expired - Lifetime
- 1997-10-16 DK DK05021714.0T patent/DK1632574T3/da active
- 1997-10-16 PT PT05021714T patent/PT1632574E/pt unknown
- 1997-10-16 EP EP97910128A patent/EP0931148B1/en not_active Expired - Lifetime
-
1999
- 1999-04-15 NO NO19991796A patent/NO326459B1/no not_active IP Right Cessation
- 1999-08-05 US US09/368,951 patent/US6352971B1/en not_active Expired - Lifetime
-
2001
- 2001-10-19 US US10/037,922 patent/US7247608B2/en not_active Expired - Fee Related
-
2006
- 2006-08-30 HK HK06109632.9A patent/HK1089206A1/xx not_active IP Right Cessation
-
2011
- 2011-03-01 HK HK11102085.9A patent/HK1148030A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1632574E (pt) | Homólogos do factor de crescimento fibroblástico | |
Gospodarowicz et al. | Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells | |
Volpert et al. | Inhibition of angiogenesis by thrombospondin-2 | |
Thomas | Fibroblast growth factors | |
Thomas et al. | Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity | |
Aono et al. | Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer | |
KR100214740B1 (ko) | 골유도조성물 | |
US5436228A (en) | Chemotactic wound healing peptides | |
KR900700617A (ko) | 뼈 및 연골 유도 조성물 | |
KR20010033484A (ko) | 각질세포 성장 인자-2 제제 | |
BR0109494A (pt) | Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas | |
KR960706559A (ko) | Bmp-12, bmp-13 및 이의 건(腱)-유도 조성물(bmp-12, bmp-13 andtendon-inducing compositions thereof) | |
BR0116507A (pt) | Fatores do crescimento de fibroblastos | |
PT86558B (pt) | Processo para a preparacao de factores de desenvolvimento de fibroblastos basicos | |
US5824647A (en) | Chemotactic wound healing peptides | |
KR880012641A (ko) | 아미노산 유도체 | |
US7892532B2 (en) | Intracellular delivery of osteoinductive proteins and peptides | |
CA2201944C (en) | Analogs of keratinocyte growth factor having enhanced temperature stability | |
AU704364B2 (en) | New protein HMW human MP52 | |
Gospodarowicz | Molecular and developmental biology aspects of fibroblast growth factor | |
EP0842274A1 (en) | Human mp52 arg protein | |
Congote | Similarities in structure and function of bovine serum erythrotropin and human insulin-like growth factor II: two fetal erythroid cell stimulating factors | |
Hashi et al. | Angiogenic activity of a fusion protein of the cell-binding domain of fibronectin and basic fibroblast growth factor | |
Benzakour et al. | Drosophila cell extracts contain a TGF-β-like activity | |
KR950703993A (ko) | 치주 조직 질환 치료제(periodonal disease remedy) |